Beigene Ltd（BGNE）财务数据BGNEBeigene Ltd

Beigene Ltd (BGNE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is BRUKINSA, accounting for 68.9% of total sales, equivalent to $690.28M. Other significant revenue streams include Tislelizumab and XGEVA. Understanding this composition is critical for investors evaluating how BGNE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Beigene Ltd maintains a gross margin of 82.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -12.01%, while the net margin is -12.12%. These profitability ratios, combined with a Return on Equity (ROE) of -23.69%, provide a clear picture of how effectively BGNE converts its operational activities into shareholder value.

In the context of the broader market, BGNE competes directly with industry leaders such as PFE and NVS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BGNE's gross margin of 82.97% stands against PFE's 67.81% and NVS's 75.39%. Such benchmarking helps identify whether Beigene Ltd is trading at a premium or discount relative to its financial performance.